MetLife Investment Management’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $457K | Buy |
63,712
+10,976
| +21% | +$78.8K | ﹤0.01% | 1720 |
|
|
2025
Q1 | $316K | Sell |
52,736
-4,014
| -7% | -$24K | ﹤0.01% | 1943 |
|
|
2024
Q4 | $443K | Buy |
56,750
+3,382
| +6% | +$26.4K | ﹤0.01% | 1867 |
|
|
2024
Q3 | $576K | Hold |
53,368
| – | – | ﹤0.01% | 1708 |
|
|
2024
Q2 | $450K | Buy |
53,368
+10,726
| +25% | +$90.4K | ﹤0.01% | 1780 |
|
|
2024
Q1 | $287K | Sell |
42,642
-213
| -0.5% | -$1.43K | ﹤0.01% | 1980 |
|
|
2023
Q4 | $252K | Hold |
42,855
| – | – | ﹤0.01% | 2103 |
|
|
2023
Q3 | $418K | Buy |
42,855
+7,620
| +22% | +$74.3K | ﹤0.01% | 1742 |
|
|
2023
Q2 | $417K | Buy |
35,235
+1,217
| +4% | +$14.4K | ﹤0.01% | 1817 |
|
|
2023
Q1 | $367K | Hold |
34,018
| – | – | ﹤0.01% | 1844 |
|
|
2022
Q4 | $393K | Hold |
34,018
| – | – | ﹤0.01% | 1799 |
|
|
2022
Q3 | $508K | Buy |
34,018
+10,628
| +45% | +$159K | ﹤0.01% | 1623 |
|
|
2022
Q2 | $211K | Buy |
23,390
+6,930
| +42% | +$62.5K | ﹤0.01% | 2284 |
|
|
2022
Q1 | $123K | Buy |
16,460
+12,193
| +286% | +$91.3K | ﹤0.01% | 2585 |
|
|
2021
Q4 | $36.6K | Sell |
4,267
-9,755
| -70% | -$83.7K | ﹤0.01% | 2473 |
|
|
2021
Q3 | $118K | Buy |
+14,022
| New | +$118K | ﹤0.01% | 2365 |
|